Publication:
Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD experts) Delphi panel

dc.contributor.coauthorTrzeciak, Magdalena
dc.contributor.coauthorRudnicka, Lidia
dc.contributor.coauthorArenberger, Petr
dc.contributor.coauthorEngin, Burhan
dc.contributor.coauthorL'vov, Andrey
dc.contributor.coauthorAlpsoy, Erkan
dc.contributor.coauthorBenáková, Nina
dc.contributor.coauthorBobko, Svetlana
dc.contributor.coauthorBorlu, Murat
dc.contributor.coauthorCzarnecka-Operacz, Magdalena
dc.contributor.coauthorElisyutina, Olga
dc.contributor.coauthorErgun, Tülin
dc.contributor.coauthorErtam, Ilgen
dc.contributor.coauthorFedenko, Elena
dc.contributor.coauthorFilipovská, Olga
dc.contributor.coauthorFomina, Daria
dc.contributor.coauthorGadzhigoroeva, Aida
dc.contributor.coauthorKojanová, Martina
dc.contributor.coauthorLesiak, Aleksandra
dc.contributor.coauthorMichenko, Anna
dc.contributor.coauthorMurashkin, Nikolay
dc.contributor.coauthorOwczarek, Witold
dc.contributor.coauthorÖzkaya, Esen
dc.contributor.coauthorPlzáková, Zuzana
dc.contributor.coauthorReich, Adam
dc.contributor.coauthorSelerova, Marie
dc.contributor.coauthorGürbüz, Burcu A.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAlper, Fatma Sibel
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:37:35Z
dc.date.issued2024
dc.description.abstractBackground There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. Methods In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. Results The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. Conclusions These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessgold
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Pfizer. The funder had the following involvement in the study: All panel members/authors received honoraria from Pfizer for their consultancy on answering the questionnaires of this study. Project coordination support including submission assistance was provided by Ferda Kiziltasat Remedium Consulting Group and was funded by Pfizer, open access journal fees are also funded by Pfizer upon acceptance of this study. BG is an employee of Pfizer.
dc.description.volume11
dc.identifier.doi10.3389/fmed.2024.1402493
dc.identifier.eissn2296-858X
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85197868597
dc.identifier.urihttps://doi.org/10.3389/fmed.2024.1402493
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22404
dc.identifier.wos1261229400001
dc.keywordsAtopic dermatitis
dc.keywordsDisease burden
dc.keywordsManagement
dc.keywordsTreatment
dc.keywordsModerate-to-severe AD
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Medicine
dc.subjectGeneral medicine
dc.subjectInternal medicine
dc.titleDisease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD experts) Delphi panel
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAlper, Fatma Sibel
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR04561.pdf
Size:
452.14 KB
Format:
Adobe Portable Document Format